Indaptus Therapeutics, Inc. - Schedule 13D Filing

This filing details a significant change in beneficial ownership of Indaptus Therapeutics, Inc. (INDP) common stock. Six reporting persons, including Yun Yao, Sino Lion Ventures Limited, Chenhao Xu, Junyi Dai, Ting Yang, and Lina Deng, have collectively acquired a substantial stake in the company. The acquisition was facilitated through a Securities Purchase Agreement dated March 19, 2026, involving the purchase of Series AA and Series AAA Convertible Non-Redeemable Preferred Stock from David Elliot Lazar for an aggregate price of $11,200,000. This preferred stock was subsequently converted into common stock. Following the transaction, Junyi Dai was appointed as the Chief Executive Officer and a member of the Board of Directors. The reporting persons may be considered a "group" for the purposes of the purchase agreement, collectively holding a significant percentage of the company's outstanding shares. Yun Yao holds 37.8% (41,991,000 shares), Sino Lion Ventures Limited and Chenhao Xu (as its controlling person) hold 35.0% (38,895,000 shares), Junyi Dai and Ting Yang each hold 10.1% (11,250,000 shares), and Lina Deng holds 5.0% (5,550,000 shares). The total outstanding shares considered for these percentages is 111,178,324.